Susquehanna International Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-14,877
| Closed | -$225K | – | 14522 |
|
|
2022
Q3 | $225K | Buy |
+14,877
| New | +$173K | ﹤0.01% | 10539 |
|
|
2022
Q2 | – | Sell |
-11,137
| Closed | -$78.5K | – | 14441 |
|
|
2022
Q1 | $101K | Buy |
+11,137
| New | +$85.8K | ﹤0.01% | 11913 |
|
|
2021
Q4 | – | Sell |
-28,483
| Closed | -$298K | – | 14288 |
|
|
2021
Q3 | $325K | Buy |
+28,483
| New | +$416K | ﹤0.01% | 10421 |
|
|
2021
Q2 | – | Sell |
-12,162
| Closed | -$217K | – | 13547 |
|
|
2021
Q1 | $217K | Sell |
12,162
-11,679
| -49% | -$202K | ﹤0.01% | 11274 |
|
|
2020
Q4 | $322K | Sell |
23,841
-28,559
| -55% | -$345K | ﹤0.01% | 9130 |
|
|
2020
Q3 | $617K | Buy |
52,400
+26,914
| +106% | +$328K | ﹤0.01% | 7237 |
|
|
2020
Q2 | $376K | Sell |
25,486
-62,341
| -71% | -$922K | ﹤0.01% | 7940 |
|
|
2020
Q1 | $1.19M | Buy |
+87,827
| New | +$1.67M | ﹤0.01% | 5002 |
|
|
2019
Q4 | – | Sell |
-120,315
| Closed | -$2.49M | – | 10956 |
|
|
2019
Q3 | $2.31M | Buy |
120,315
+5,140
| +4% | +$118K | ﹤0.01% | 3918 |
|
|
2019
Q2 | $3.4M | Buy |
+115,175
| New | +$4.44M | ﹤0.01% | 3258 |
|
|
2019
Q1 | – | Sell |
-14,410
| Closed | -$634K | – | 10156 |
|
|
2018
Q4 | $520K | Sell |
14,410
-4,035
| -22% | -$189K | ﹤0.01% | 5970 |
|
|
2018
Q3 | $1.14M | Buy |
18,445
+8,650
| +88% | +$556K | ﹤0.01% | 4983 |
|
|
2018
Q2 | $662K | Buy |
+9,795
| New | +$548K | ﹤0.01% | 6243 |
|
|
2018
Q1 | – | Sell |
-178,957
| Closed | -$10M | – | 10459 |
|
|
2017
Q4 | $10.7M | Buy |
178,957
+122,357
| +216% | +$7.42M | ﹤0.01% | 1766 |
|
|
2017
Q3 | $2.75M | Buy |
56,600
+44,121
| +354% | +$2.41M | ﹤0.01% | 3364 |
|
|
2017
Q2 | $656K | Sell |
12,479
-8,196
| -40% | -$382K | ﹤0.01% | 6115 |
|
|
2017
Q1 | $938K | Sell |
20,675
-5,729
| -22% | -$256K | ﹤0.01% | 5256 |
|
|
2016
Q4 | $999K | Sell |
26,404
-146,181
| -85% | -$5.53M | ﹤0.01% | 5542 |
|
|
2016
Q3 | $6.51M | Buy |
+172,585
| New | +$3.81M | ﹤0.01% | 1935 |
|
|
2016
Q2 | – | Sell |
-18,915
| Closed | -$306K | – | 9544 |
|
|
2016
Q1 | $230K | Buy |
+18,915
| New | +$299K | ﹤0.01% | 7738 |
|
|
2015
Q4 | – | Sell |
-61,808
| Closed | -$1.44M | – | 10152 |
|
|
2015
Q3 | $1.1M | Buy |
+61,808
| New | +$1.12M | ﹤0.01% | 5551 |
|
|
2015
Q2 | – | Sell |
-27,845
| Closed | -$510K | – | 10585 |
|
|
2015
Q1 | $873K | Buy |
+27,845
| New | +$807K | ﹤0.01% | 6031 |
|
Susquehanna International Group's AERI Position: Q4 2022 in Review
Susquehanna International Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 14,877 shares — an estimated $225K sold.
Susquehanna International Group first reported a position in AERI in Q1 2015 and held it in 22 quarters. The position peaked at $10.7M in Q4 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Susquehanna International Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Susquehanna International Group sold 14,877 Aerie Pharmaceuticals shares in Q4 2022, an estimated $225K.
- Susquehanna International Group first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 22 quarters.
- Susquehanna International Group's Aerie Pharmaceuticals position peaked at $10.7M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.